Skip to main content
Back
SRPT logo

Sarepta Therapeutics, Inc.

Data quality: 100%
SRPT
NASDAQ Healthcare Biotechnology
$17.71
▲ $1.02 (6.11%)
Mkt Cap: 1.86B
Day Range
$16.67 $17.78
52-Week Range
$10.42 $76.67
Volume
2,940,794
50D / 200D Avg
$18.99 / $20.15
Prev Close
$16.69

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -2.6 0.4
P/B 1.6 2.9
ROE % -53.5 3.8
Net Margin % -32.5 3.9
Rev Growth 5Y % 33.0 10.0
D/E 0.9 0.2

Key Takeaways

Revenue grew 33.03% annually over 5 years — strong growth
Earnings declined -403.27% over the past year
Negative free cash flow of -307.45M
PEG of 0.01 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 17.45%
Capital efficient — spends only 4.64% of revenue on capex

Growth

Revenue Growth (5Y)
33.03%
Revenue (1Y)15.58%
Earnings (1Y)-403.27%
FCF Growth (3Y)N/A

Quality

Return on Equity
-53.47%
ROIC-22.63%
Net Margin-32.45%
Op. Margin-29.92%

Safety

Debt / Equity
0.91
Current Ratio2.32
Interest Coverage-67.60

Valuation

P/E Ratio
-2.61
P/B Ratio1.63
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 15.58% Revenue Growth (3Y) 32.97%
Earnings Growth (1Y) -403.27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 33.03% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.20B Net Income (TTM) -713.41M
ROE -53.47% ROA -21.30%
Gross Margin 59.90% Operating Margin -29.92%
Net Margin -32.45% Free Cash Flow (TTM) -307.45M
ROIC -22.63% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.91 Current Ratio 2.32
Interest Coverage -67.60 Dividend Yield 0.00%
Valuation
P/E Ratio -2.61 P/B Ratio 1.63
P/S Ratio 0.85 PEG Ratio 0.01
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.86B Enterprise Value 2.10B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.20B 1.90B 1.24B 933.01M 701.89M
Net Income -713.41M 235.24M -535.98M -703.49M -418.78M
EPS (Diluted) -7.13 2.34 -5.80 -8.03 -5.15
Gross Profit 1.32B 1.58B 1.09B 793.02M 604.84M
Operating Income -657.77M 218.08M -267.82M -536.20M -459.71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3.35B 3.96B 3.26B 3.13B 3.15B
Total Liabilities 2.21B 2.44B 2.41B 2.74B 2.22B
Shareholders' Equity 1.14B 1.53B 859.34M 384.95M 928.01M
Total Debt 1.04B 1.34B 1.40B 1.62B 1.15B
Cash & Equivalents 801.28M 1.10B 428.43M 966.78M 2.12B
Current Assets 2.54B 3.07B 2.58B 2.56B 2.60B
Current Liabilities 1.10B 731.68M 653.66M 619.60M 452.73M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#181 of 616
50

Recent Activity

Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026